hotspot -WSS

hotspot

author：entertainment 2025-08-11 11:44:23 - browse：73

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Abbott's new heart device gets FDA advisory panel nod

Wikipedia

WSS

Abbott's new heart device gets FDA advisory panel nod

ACIP vaccine advisory panel sees its vacancies filled

FDA endorses new sterilization method for medical devices

Ebola vaccine can save some who are already sick, per new study

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

What causes osteoarthritis? Researchers study link to brain protein

knowledge

hotspot

hotspot

Cancer drug shortages should be causing more outrage

CVS is on a mission to consolidate health care. Will it work?

Hepatitis C has a cure — but many Americans still lack access to it

Bernie Sanders gets little from pharma CEOs on drug prices

Jerome Adams on the need for new antivirals for Covid

Having children helps parents live longer, especially after age 80

Supreme Court strikes down use of affirmative action

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

The high cost of giving birth even with insurance

What causes osteoarthritis? Researchers study link to brain protein

explore

STAT Boddities: What happens to the brain when we get scared?

Immunocompromised patients offer clues on chronic Covid

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Study gives hint on South Asians’ higher risk of cardiovascular disease

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Bernie Sanders gets little from pharma CEOs on drug prices

leisure time

Wikipedia

explore

entertainment